Bioinformatics and Computational Biology Core

生物信息学和计算生物学核心

• 批准号: 10250437
• 负责人: Kun Huang
• 金额: $ 89.29万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250437
• 关键词: Affect; Aging; Alzheimer' s Disease; Bioinformatics; Biological Process; Cessation of life; Charge; Cognitive; Communities; Computational Biology; Coupled; Data; Data Analyses; Data Set; Dementia; Deterioration; Diagnosis; Disease; Drug Targeting; Elderly; Etiology; Infrastructure; Lead; Medicine; Memory; Methods; Mitochondria; Neuroglia; Pharmaceutical Preparations; Play; Population; Process; Research; Role; Source; Symptoms; Testing; Virus Diseases; Visualization; base; cell mediated immune response; computerized data processing; curative treatments; data integration; drug candidate; drug development; drug discovery; drug repurposing; druggable target; infrastructure development; novel; novel therapeutics; technology development

Project Summary Alzheimer’s disease (AD) affects about 40 million people worldwide today, and is the most common form of dementia found predominantly in elderly people. AD is a highly heterogeneous disease with major symptoms including progressive memory and cognitive domain deterioration over years, which eventually leads to death about 3-9 years after diagnosis. During the past few decades, many hypotheses have been proposed as potential mechanisms for AD, which involve multiple biological processes such as proteopathogenesis, mitochondrial abnormality, viral infection, and other glia cell-mediated immunological response. However, the disease etiology and mechanism still remain unclear, and currently, there is still no curative treatment for AD. During the past years, multiple endeavors have been taken by the AD research community to identify potential drug targets. Among them, AMP ADis leading the charge of generating drug target candidates based on evidences from multiple studies. With the large amount of data accumulated from these projects, it calls for deeper analysis coupled with extensive downstream drug development technologies to refine the target candidate lists and also identify potential new targets as well as possible drugs. The ADDD project aims to establish the entire workflow for this process and ambitiously discover new drugs for AD. As part of the overall effort of the our ADDD project, the Bioinformatics and Computational Biology Core (BCB Core) will play a critical role in this team. The BCB Core will play three major roles. First, the BCB Core will lead the development of the infrastructure enabling curation, processing, analysis, visualization, and sharing of large AD datasets from this project as well as public sources. Secondly, the BCB Core will develop and establish advanced and novel data integration methods for predicting and prioritizing druggable targets as well as potential repurposing drug candidates for AD. Last but not the least, the BCB Core will provide bioinformatics data processing and analysis support for the entire project covering the lifecycle of the AD drug target identification and testing by closely collaborating and coordinating with other cores for the ADDD center.

项目摘要 阿尔茨海默病(AD)目前影响着全球约4000万人，是最常见的 痴呆症主要见于老年人。AD是一种具有主要症状的高度异质性疾病。 包括多年来的渐进性记忆和认知领域的恶化，最终导致死亡 大约在确诊后3-9年。在过去的几十年里，许多假设被提出作为潜在的 阿尔茨海默病的机制，涉及蛋白病理发生、线粒体等多个生物学过程 异常、病毒感染等神经胶质细胞介导的免疫反应。然而，疾病病因学 且发病机制尚不清楚，目前尚无治疗AD的根治方法。在过去 多年来，AD研究界采取了多种努力来确定潜在的药物靶点。 其中，AMP Adis牵头根据来自以下方面的证据生成药物靶标候选 多项研究。由于这些项目积累了大量的数据，需要进行更深入的分析 再加上广泛的下游药物开发技术，以完善目标候选名单，还 确定潜在的新靶点以及可能的药物。ADDD项目旨在建立整个工作流程 并雄心勃勃地发现治疗AD的新药。作为我们ADDD项目整体努力的一部分， 生物信息学和计算生物学核心(BCB Core)将在这个团队中发挥关键作用。BCB CORE将扮演三个主要角色。首先，BCB核心将领导基础设施支持的开发 管理、处理、分析、可视化和共享来自该项目以及公共的大型AD数据集 消息来源。其次，BCB核心将开发和建立先进和新颖的数据集成方法，以 预测和优先考虑AD的可用药靶点以及潜在的再利用候选药物。最后一次但 同样重要的是，BCB Core将为整个项目提供生物信息学数据处理和分析支持 通过密切合作和协调，覆盖AD药物靶标识别和测试的整个生命周期 与ADDD中心的其他核心一起使用。